EP4647129A3 — METHOD FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-A!PYRROLO[2,3-E!PYRAZINE-8-YL)-N-(2,2,2-TRIFLUORETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID FORMS THEREIN
Assigned to AbbVie Inc · Expires 2025-12-31 · 0y expired
What this patent protects
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3 H- imidazo[1,2- a ]pyrrolo[2,3- e ]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (inclu…
USPTO Abstract
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3 H- imidazo[1,2- a ]pyrrolo[2,3- e ]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Drugs covered by this patent
- Rinvoq (upadacitinib) · AbbVie Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.